Efficacy of Nevirapine-Based HAART in HIV-1-Infected, Treatment-Naive Persons with High and Low Baseline Viral Loads

REFERENCES

• PaleIla FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865–1873.
   PubMed Web of Science ®Google Scholar
• Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS trial. JAMA. 1998;279:930–937.
   PubMed Web of Science ®Google Scholar
• Squires K, Johnson V, Katlama C, et al. The Atlantic study: A randomized, open-label study to evaluate the efficacy and safety of three triple-combination therapies aimed at different HIV targets in antiretroviral naive HIV-1 infected patients (final 48 weeks analysis). Presented at: 13th Inter-national AIDS Conference; July 2000; Durban, South Africa. Abstract LbPeB7046.
   Google Scholar
• Podzamczer D, Ferrer E, Consiglio E, et al. Preliminary results of a randomized multicenter study comparing Combivir (ZDV/3TC) plus nelfinavir or nevirapine in HIV-infected naive patients (COMBINE study). Presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 2001; Chicago, IL. Abstract 327.
   Google Scholar
• Floridia M, Bucciardini R, Ricciardulli D, et al. A random-zed, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. J Acquir Immun Defic Syndr Hum Retrovirol. 1999;20:11–19.
   PubMedGoogle Scholar
• Staszewski S, Keiser P, Gathe J, et al. Comparison of antiviral response with abacavir/Combivir to indinavir/ Combivir in therapy-naive adults at 48 weeks (CNA3005). Presented at: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1999; San Francisco, CA. Abstract 505.
   Google Scholar
• Raffi F, Reliquet V, Ferre V, et al. d4T + qd ddl + nevirapine (bid or qd) in antiretroviral-naive HIV-1 infected patients: 1-year results of the VIRGO study. Presented at: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1999; San Francisco, CA. Abstract 1978.
   Google Scholar
• Raffi F, Reliquet V, Ferre V, et al. The VIRGO study: Nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1 infected adults. Antiviral Ther. 2000;5:267–272.
   PubMed Web of Science ®Google Scholar
• Chowdhury C, Skinner C, Latzke M, et al. Combination therapy with nevirapine in antiretroviral naive patients is effective in patients with high baseline viral load. Presented at: 4th International Congress on Drug Therapy in HIV Infection; November 1998; Glasgow, Scotland. Abstract P106.
   Google Scholar
• Nelson MR, Fisher M, Shaw A, et al. The durability of virological response in individuals with high viral load to non-nucleoside reverse transcriptase inhibitor therapy. Presented at: 5th International Congress on Drug Therapy in HIV Infection; October 2000; Glasgow, Scotland. Abstract P102.
   Google Scholar
• Pollard RB, 1090 Team. Factors predictive of durable HIV suppression in a randomized double blind trial with nevirapine (NVP), zidovudine (ZDV) and lamivudine (3TC) in treatment-naive (ARV-n) patients with advanced AIDS. Presented at: 7th Conference on Retroviruses and Opportunistic Infections; January-February 2000; San Francisco, CA. Abstract 517.
   Google Scholar
• Kaspar R, Werntz G, DuBois DB. Early results of combined stavudine, lamivudine, and nevirapine: A twice daily, well-tolerated, protease inhibitor-sparing regimen for the treatment of HIV-1 infection. Presented at: 5th Conference on Retroviruses and Opportunistic Infections; February 1998; Chicago, IL. Abstract 696.
   Google Scholar
• Russell DB, Bal J, Anderson JStC, Moore R, Russell JM. The efficacy of nevirapine at low versus high viral loads. Presented at: 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; October 1999; Lisbon, Portugal. Abstract 518.
   Google Scholar
• Skowron G, Street JC, Obee EM. Viral load suppression of highly active antiretroviral therapy (HAART) correlates with baseline CD4+ cell count, but not with viral load. Presented at: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1999; San Francisco, CA. Abstract 1991.
   Google Scholar
• Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Meta-analysis of the effectiveness of triple-combination therapy in antiretroviral naive HIV-1 infected adults. Presented at: 7th Conference on Retroviruses and Opportunistic Infections; January-February 2000; San Francisco, CA. Abstract 519.
   Google Scholar
• Miller V, Staszewski S, Sabin C, et al. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. J Infect Dis. 1999;180:530–533.
   PubMed Web of Science ®Google Scholar
• van der Valk M, Reiss P, Molhuizen H, et al. Nevirapine-containing potent antiretroviral therapy results in an anti-atherogenic plasma lipid profile: Results from the Atlantic study. Presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 2001; Chicago, IL. Abstract 654B.
   Google Scholar
• Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13:805–810.
   PubMed Web of Science ®Google Scholar
• Raffi F, Bonnet B, Ferré V, et al. Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA. Clin Infect Dis. 2000;31:1274–1278.
   PubMed Web of Science ®Google Scholar